REMEGEN (09995) has announced its preliminary financial results for the 2025 fiscal year. The company achieved total operating revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36%. Profit attributable to owners of the parent company was RMB 709 million, marking a turnaround from a loss in the same period last year. Basic earnings per share were RMB 1.29. The company stated that the increase in operating revenue was primarily due to higher sales volumes of Telitacicept for Injection and Disitamab Vedotin for Injection, leading to increased sales revenue. Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Telitacicept outside the Greater China region, resulting in a significant increase in technology licensing revenue.